ABSTRACT
Altogether 77 children aged up to 3 years with acute lymphoblastic leukemia (ALL) were examined for the immunological phenotype of blast cells. L1, L1/L2, L2/L1, L2 variants of ALL and the undifferentiated one were established in accordance with criteria of the FAB classification. T1, zero and Ia immunosubvariants were recorded most frequently. Mature cell T2 and pre-B variants (3 and 2 cases, respectively) were rare; B-cellular acute lymphoblastic leukemia was lacking; the "common" subvariant was revealed in 28 patients. The patients' age produced the highest effect on the prognosis: the significantly least disease standing and remissions were noted in a group of children under 2 years as compared to those aged 2 to 3 years. As for immunological markers, expression of Thy1-antigen exerted an unfavourable effect on the prognosis and duration of the first remission.
Subject(s)
Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis , Antibodies, Monoclonal , Biomarkers , Child, Preschool , Humans , Infant , Infant, Newborn , Precursor Cell Lymphoblastic Leukemia-Lymphoma/immunology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality , PrognosisABSTRACT
The antigen detectable with monoclonal antibodies ICO-11 was studied in cells of 33 patients with acute lymphoblastic leukemia (ALL) and 47 patients with acute non-lymphoblastic leukemia (ANLL). The incidence rate of antigen-positive cases in ALL comprised 39.4%, in ANLL 35.4%. The presence of antigen in blasts in ALL did not influence the disease prognosis. The presence of ICO-11+ blasts in ANLL was characteristic of the group of patients with more favourable prognosis: a higher survival rate, due to a higher frequency of remissions, a longer life-time in the absence of remission. Basing on the clinico-hematological data ICO-11+ group could not be identified as more favourable prognostically.
Subject(s)
Antibodies, Monoclonal/immunology , Antigens, Neoplasm/immunology , Biomarkers, Tumor/immunology , Leukemia, Myeloid, Acute/immunology , Adult , Antibodies, Monoclonal/classification , Antigens, Neoplasm/analysis , Biomarkers, Tumor/analysis , Humans , Leukemia, Myeloid, Acute/diagnosis , Leukemia, Myeloid, Acute/mortality , Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis , Precursor Cell Lymphoblastic Leukemia-Lymphoma/immunology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality , Prognosis , Time FactorsABSTRACT
Seventy-two children with acute nonlymphoblastic leukemia (ANLL) have been studied for expression of different antigens on blast cells with the use of monoclonal antibodies. Myeloid antigens (C3bi; X-hapten) were identified on blast cells most frequently, 58.3%, Ia-like antigen was found in 55% and LFA-1 in 34% of cases. The expression of all antigens except that of LFA-1 was independent on FAB-subtype. It seems necessary in clinical practice to type ANLL cells for the expression of T-cell and myeloid antigens that are of prognostic significance.
Subject(s)
Immunologic Tests , Leukemia, Myeloid, Acute/diagnosis , Antibodies, Monoclonal , Antigens, Neoplasm/analysis , Child , Humans , Leukemia, Myeloid, Acute/immunology , Prognosis , T-Lymphocytes/immunologyABSTRACT
The results of radiation therapy of 117 patients with squamous cell lung carcinoma taking into account yearly survival were analyzed. Clinico-laboratory and roentgenological factors of prognosis were identified. The use of methods of mathematical statistics and a method of structural risk minimization made it possible to work out a decision rule permitting prognosis of yearly outcome of disease with the minimal probability of 72% even before the start of radiation therapy.
Subject(s)
Carcinoma, Squamous Cell/radiotherapy , Lung Neoplasms/radiotherapy , Adult , Aged , Female , Humans , Male , Middle Aged , Prognosis , Risk Factors , Time FactorsSubject(s)
Colonic Neoplasms/mortality , Rectal Neoplasms/mortality , Adult , Aged , Colonic Neoplasms/surgery , Computers , Female , Humans , Male , Middle Aged , Prognosis , Rectal Neoplasms/surgery , Time FactorsABSTRACT
A procedure for individual prognosis of surgical treatment of large bowel cancer based on certain clinico-morphological factors is discussed. The procedure is based on the criterion of three-year survival. Computer was used in the evaluation of the prognostic value of each factor using the data available at the Center. The most informative factors were selected to develop a model which gives a reliable prognosis for each case. Application of a multivariate statistical method yielded an optimal combination of prognostic factors and a decision rule was constructed. The credibility of the rule as evaluated on the basis of an additional sample proved to be 91.4%.